Abbott Laboratories stock holds steady on its broad health care base

Abbott Laboratories (ISIN US0028241000) is a large-cap health care company whose business spans diagnostics, medical devices, nutrition and branded medicines. The company trades on the New York Stock Exchange under ABT, giving U.S. investors direct access to a diversified medical-products franchise.

Business model

Abbott's portfolio is built around recurring demand in health care rather than a single product cycle, which makes the company structurally different from narrower device or diagnostics peers. That mix can matter for revenue stability because weakness in one segment can be offset by strength in another.

Market context

For investors, the key read-through is that Abbott is less of a one-product story and more of a platform business with exposure to global health spending. In a sector where earnings durability often commands a premium, that breadth is a meaningful part of the equity case.

Representative product

One of Abbott's best-known franchises is FreeStyle Libre, its continuous glucose monitoring system for people with diabetes. The product illustrates the company's device-led approach: recurring sensor usage, patient retention and a direct tie to long-term chronic-care demand.

Stock context

Abbott Laboratories stock closed at $0 as of July 14, 2026, 11:01 p.m. ET.